Crystal polymorphism in chemical process development.

Polymorphism in molecular crystals is a prevalent phenomenon and is of great interest to the pharmaceutical community. The solid-state form is a key quality attribute of a crystalline product. Inconsistencies in the solid phase produced during the manufacturing and storage of drug substances and drug products may have severe consequences. It is essential to understand the solid-state behavior of the drug and to judiciously select the optimal solid form for development. This review highlights the pervasiveness and relevance of polymorphism and describes solid form screening and selection processes. Moreover, case studies on controlling polymorphs from a chemical development perspective are provided.

[1]  D. Fox.  Physics and Chemistry of the Organic Solid State , 1963 .

[2]  Polymorphie bei Arzneistoffen , 1975 .

[3]  S. Byrn.  Solid state chemistry of drugs , 1982 .

[4]  R. Davey,et al.  The kinetics of solvent-mediated phase transformations , 1985, Proceedings of the Royal Society of London. A. Mathematical and Physical Sciences.

[5]  S. Görög,et al.  The polymorphism of cimetidine. , 1985, Journal of pharmaceutical and biomedical analysis.

[6]  T. Matsubara,et al.  Pseudo-polymorphism and crystalline transition of magnesium stearate , 1992 .

[7]  A. P. Lötter,et al.  Kinetic study of the solid-state photolytic degradation of two polymorphic forms of furosemide , 1992 .

[8]  A. P. Lötter,et al.  Polymorphs of nitrofurantoin. I. Preparation and X-ray crystal structures of two monohydrated forms of nitrofurantoin , 1993 .

[9]  P. York,et al.  Dehydration of theophylline monohydrate powder — effects of particle size and sample weight , 1994 .

[10]  A. P. Lötter,et al.  Hydration of drug molecules: cavityinclusion of water in crystals of loperamide hydrochloride tetrahydrate , 1995 .

[11]  Gregory A. Stephenson,et al.  Purification of Dirithromycin. Impurity Reduction and Polymorph Manipulation , 1997 .

[12]  R. Docherty,et al.  Polymorphism in Molecular Crystals: Stabilization of a Metastable Form by Conformational Mimicry , 1997 .

[13]  Alfons Grunenberg.  Polymorphie und Thermische Analyse pharmazeutischer Wirkstoffe , 1997 .

[14]  G. Stephenson,et al.  Formation of isomorphic desolvates: creating a molecular vacuum. , 1998, Journal of pharmaceutical sciences.

[15]  Wolfgang Beckmann,et al.  Development of a Seeding Technique for the Crystallization of the Metastable A Modification of Abecarnil , 1998 .

[16]  Robin K. Harris,et al.  NMR study of desmotropy in Irbesartan, a tetrazole-containing pharmaceutical compound , 1998 .

[17]  H. Brittain.  Polymorphism in Pharmaceutical Solids , 1999 .

[18]  G. Desiraju,et al.  Pseudopolymorphism: occurrences of hydrogen bonding organic solvents in molecular crystals , 1999 .

[19]  Wolfgang Beckmann,et al.  Seeding the Desired Polymorph: Background, Possibilities, Limitations, and Case Studies , 2000 .

[20]  C. A. Mitchell,et al.  Crystallization and Polymorphism of Conformationally Flexible Molecules: Problems, Patterns, and Strategies , 2000 .

[21]  S. Chemburkar,et al.  Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development , 2000 .

[22]  A better drug for Alzheimer's , 2000 .

[23]  Michael B. Hursthouse,et al.  Over one hundred solvates of sulfathiazole , 2001 .

[24]  S. Byrn,et al.  Chemical reactivity in solid-state pharmaceuticals: formulation implications. , 2001, Advanced drug delivery reviews.

[25]  A. Myerson,et al.  Effect of Additives on the Transformation Behavior of l-Phenylalanine in Aqueous Solution , 2001 .

[26]  Taking Advantage of Polymorphism To Effect an Impurity Removal: Development of a Thermodynamic Crystal Form of (R,R)-Formoterol Tartrate , 2002 .

[27]  Lian Yu.  Color Changes Caused by Conformational Polymorphism: Optical-Crystallography, Single-Crystal Spectroscopy, and Computational Chemistry , 2002 .

[28]  J. Elguero,et al.  Polymorphism vs. Desmotropy: The Cases of 3‐Phenyl‐ and 5‐Phenyl‐ 1H‐pyrazoles and 3‐Phenyl‐1H‐indazole , 2002 .

[29]  M. Ticehurst,et al.  Application of slurry bridging experiments at controlled water activities to predict the solid-state conversion between anhydrous and hydrated forms using theophylline as a model drug. , 2002, International journal of pharmaceutics.

[30]  H. Brittain.  Effects of mechanical processing on phase composition. , 2002, Journal of pharmaceutical sciences.

[31]  Joel Bernstein,et al.  Polymorphism in Molecular Crystals , 2002 .

[32]  A. R. Parsons,et al.  Automated Measurement of Metastable Zones for Pharmaceutical Compounds , 2003 .

[33]  Stephen R. Byrn,et al.  Anhydrates and Hydrates of Olanzapine: Crystallization, Solid-State Characterization, and Structural Relationships , 2003 .

[34]  B. K. Hodnett,et al.  Inclusion of the Stable Form of a Polymorph within Crystals of Its Metastable Form , 2003 .

[35]  Lian Yu,et al.  Nucleation of one polymorph by another. , 2003, Journal of the American Chemical Society.

[36]  M. Peterson,et al.  Crystallization and Transformation of Acetaminophen Trihydrate , 2003 .

[37]  W. David,et al.  Pressure-induced formation of a solvate of paracetamol. , 2003, Chemical communications.

[38]  A. S. Wood,et al.  The Chemical Development and Scale-Up of Sampatrilat1 , 2003 .

[39]  Michael J Cima,et al.  High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.

[40]  Lawrence X. Yu,et al.  Scientific Considerations of Pharmaceutical Solid Polymorphism in Abbreviated New Drug Applications , 2003, Pharmaceutical Research.

[41]  G. Desiraju.  Counterpoint: what's in a name? , 2004 .

[42]  Alex M. Chen,et al.  Drying an Organic Monohydrate: Crystal Form Instabilities and a Factory-Scale Drying Scheme to Ensure Monohydrate Preservation , 2004 .

[43]  K. Seddon.  Pseudopolymorph: A Polemic , 2004 .

[44]  W. Curatolo,et al.  Drug polymorphism and dosage form design: a practical perspective. , 2004, Advanced drug delivery reviews.

[45]  R. W. Rousseau,et al.  Characterization and solid-state transformations of the pseudopolymorphic forms of sodium naproxen , 2004 .

[46]  S. Rohani,et al.  Improving the filterability and solid density of ranitidine hydrochloride Form 1. , 2004, Journal of pharmaceutical sciences.

[47]  S. Black,et al.  Increased Chemical Purity Using a Hydrate , 2004 .

[48]  J. Bauer,et al.  Ritonavir: An Extraordinary Example of Conformational Polymorphism , 2001, Pharmaceutical Research.

[49]  Abu T M Serajuddin,et al.  Trends in solubility of polymorphs. , 2005, Journal of pharmaceutical sciences.

[50]  J. Bernstein.  And Another Comment on Pseudopolymorphism , 2005 .

[51]  Lian Yu,et al.  Cross-nucleation between ROY polymorphs. , 2005, Journal of the American Chemical Society.

[52]  H. Brittain.  Polymorphism and solvatomorphism 2004. , 2005, Profiles of drug substances, excipients, and related methodology.

[53]  Saikat Roy,et al.  Thermochemical Analysis of Venlafaxine Hydrochloride Polymorphs 1−5† , 2005 .

[54]  William Jones,et al.  Occurrence of pharmaceutically acceptable anions and cations in the Cambridge Structural Database. , 2005, Journal of pharmaceutical sciences.

[55]  Polymorphism in processes of crystallization in solution , 2005 .

[56]  David J W Grant,et al.  Identifying the Stable Polymorph Early in the Drug Discovery–Development Process , 2005, Pharmaceutical development and technology.

[57]  Rolf Hilfiker,et al.  POLYMORPHISM , 1945 .

[58]  M. Mitchell,et al.  Polymorph and Particle Size Control of PPAR Compounds PF00287586 and AG035029 , 2006 .

[59]  P. Dell'orco,et al.  A study of variable hydration states in topotecan hydrochloride. , 2006, Journal of pharmaceutical and biomedical analysis.

[60]  A. Nangia.  Pseudopolymorph: retain this widely accepted term , 2006 .

[61]  Martin Müller,et al.  Process Development Strategy to Ascertain Reproducible API Polymorph Manufacture , 2006 .

[62]  U. Griesser.  The Importance of Solvates , 2006 .

[63]  G. Desiraju,et al.  On the polymorphism of aspirin: crystalline aspirin as intergrowths of two "polymorphic" domains. , 2007, Angewandte Chemie.

[64]  N. Rodríguez-Hornedo,et al.  Solvent Systems for Crystallization and Polymorph Selection , 2007 .

[65]  G. Desiraju,et al.  Tautomeric polymorphism in omeprazole. , 2007, Chemical communications.

[66]  W. Cabri,et al.  Polymorphisms and Patent, Market, and Legal Battles: Cefdinir Case Study , 2007 .

[67]  Polymorphic Generation through Solvent Selection: Ranitidine Hydrochloride , 2007 .

[68]  W. Motherwell,et al.  Organic crystal hydrates : what are the important factors for formation , 2007 .

[69]  G. P. Stahly.  Diversity in Single- and Multiple-Component Crystals. The Search for and Prevalence of Polymorphs and Cocrystals , 2007 .

[70]  H. Brittain,et al.  Polymorphism and solvatomorphism 2005. , 2007, Journal of pharmaceutical sciences.

[71]  R. K. Jetti,et al.  Conformational Polymorphism in Oxybuprocaine Hydrochloride , 2008 .

[72]  A. Blackburn,et al.  One-solvent polymorph screen of carbamazepine. , 2008, International journal of pharmaceutics.

[73]  G. P. Martin,et al.  Polymorphic control of inhalation microparticles prepared by crystallization. , 2008, International journal of pharmaceutics.

[74]  Yong Cui,et al.  Evaluation of hydrate-screening methods. , 2008, Journal of pharmaceutical sciences.

[75]  H. Brittain.  Polymorphism and solvatomorphism 2006. , 2008, Journal of pharmaceutical sciences.

[76]  P. Young,et al.  The Influence of Lactose Pseudopolymorphic Form on Salbutamol Sulfate–Lactose Interactions in DPI Formulations , 2008, Drug development and industrial pharmacy.

[77]  Jonathan M Goodman,et al.  Polymorph control: past, present and future. , 2008, Drug discovery today.

[78]  Crystal polymorphism in antioxidant-metal deactivator 1,2-bis(3,5-di-tert-butyl-4-hydroxyhydrocinnamoyl)hydrazine , 2008 .

[79]  M. Jozwiakowski,et al.  Alteration of the Solid State of the Drug Substances: Polymorphs, Solvates, and Amorphous Forms , 2008 .

[80]  I. Popov,et al.  Development and metrological characterization of quantitative X-ray diffraction phase analysis for the mixtures of clopidogrel bisulphate polymorphs. , 2008, Journal of pharmaceutical and biomedical analysis.

[81]  Darragh Murnane,et al.  Crystallization and Crystallinity of Fluticasone Propionate , 2008 .

[82]  M. Descamps,et al.  Evidence for a New Crystalline Phase of Racemic Ibuprofen , 2008, Pharmaceutical Research.

[83]  Crystallisation Design Space: Avoiding a Hydrate in a Water-Based Process , 2009 .

[84]  R. Tessadri,et al.  Stability of Solvates and Packing Systematics of Nine Crystal Forms of the Antipsychotic Drug Aripiprazole , 2009 .

[85]  George Zhou,et al.  A Novel Crystallization Methodology To Ensure Isolation of the Most Stable Crystal Form , 2009 .

[86]  Geoff G. Z. Zhang,et al.  Chapter 2 – Crystalline and Amorphous Solids , 2009 .

[87]  F. Puel,et al.  Polymorphism in Processes of Crystallization in Solution: A Practical Review , 2009 .

[88]  H. Brittain.  Polymorphism and solvatomorphism 2007. , 2009, Journal of pharmaceutical sciences.

[89]  A Practical Approach for Using Solubility to Design Cooling Crystallisations , 2009 .

[90]  M. Al-Omar,et al.  Chapter 3 famotidine. , 2009, Profiles of drug substances, excipients, and related methodology.

[91]  H. Brittain,et al.  Polymorphism and solvatomorphism 2008. , 2010, Journal of pharmaceutical sciences.

[92]  R. W. Rousseau,et al.  Characterization of Solvates Formed by Sodium Naproxen and an Homologous Series of Alcohols , 2010 .

[93]  Keith R Horspool,et al.  Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. , 2010, Journal of pharmaceutical sciences.

[94]  Process Research and Development of a MTP Inhibitor: Another Case of Disappearing Polymorphs upon Scale-up , 2010 .

[95]  Vishal M Sonje,et al.  Atorvastatin calcium. , 2010, Profiles of drug substances, excipients, and related methodology.

[96]  N. Yagoubi,et al.  Polymorphism of Irganox 1076: Discovery of new forms and direct characterization of the polymorphs on a medical device by Raman microspectroscopy. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[97]  B. K. Hodnett,et al.  Mechanistic Features of Polymorphic Transformations: The Role of Surfaces , 2010 .

[98]  S. Velaga,et al.  Polymorphism in acesulfame sweetener: structure-property and stability relationships of bending and brittle crystals. , 2010, Chemical communications.

[99]  Suciati,et al.  Clopidogrel bisulfate. , 2010, Profiles of drug substances, excipients, and related methodology.

[100]  Lian Yu.  Polymorphism in molecular solids: an extraordinary system of red, orange, and yellow crystals. , 2010, Accounts of chemical research.

[101]  E. Kwong,et al.  Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. , 2010, Journal of medicinal chemistry.

[102]  J. Rantanen,et al.  Towards effective solid form screening. , 2010, Journal of pharmaceutical sciences.

[103]  Development of Drug Substances as Mixture of Polymorphs: Studies to Control Form 3 in Casopitant Mesylate , 2010 .

[104]  Motohiro Shiraki.  Physical characterization of TRK-720 hydrate, the very late antigen-4 (VLA-4) inhibitor, as a solid form for inhalation: preparation of the hydrate by solvent exchange among its solvates and mechanistical considerations. , 2010, Journal of pharmaceutical sciences.

[105]  Christopher Seadeek,et al.  A thermodynamic-based approach to analyzing a highly solvating polymorphic system: the desolvation window method. , 2011, Journal of pharmaceutical sciences.